<DOC>
	<DOCNO>NCT01077726</DOCNO>
	<brief_summary>This single arm study ass efficacy Xeloda treatment brain metastasis breast cancer patient central nervous system ( CNS ) progression whole brain radiotherapy . Patients receive xeloda 1000mg/m2 po bid day 1-14 3 week cycle . The anticipated time study treatment disease progression , target sample size &lt; 100 individual .</brief_summary>
	<brief_title>A Study Xeloda ( Capecitabine ) Breast Cancer Patients With Central Nervous System ( CNS ) Progression</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>female patient , &gt; =18 year age ; breast cancer ; CNS progression radiosurgery + whole brain radiotherapy , whole brain radiotherapy alone ; least one measurable lesion ; ECOG performance status 02. prior systemic treatment brain metastasis ; prior disease progression Xeloda treatment ; previous history cancer ( curatively treat basal squamous cell cancer skin situ cancer cervix ) previous 5 year ; clinically significant cardiovascular disease .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>